Since Dynavax Technologies Corporation (NASDAQ:DVAX) and XBiotech Inc. (NASDAQ:XBIT) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of both companies.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dynavax Technologies Corporation||8.20M||59.02||158.90M||-2.36||0.00|
Demonstrates Dynavax Technologies Corporation and XBiotech Inc. earnings per share, top-line revenue and valuation.
Table 2 has Dynavax Technologies Corporation and XBiotech Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Dynavax Technologies Corporation||-1,937.80%||-86.2%||-50.5%|
Volatility & Risk
Dynavax Technologies Corporation has a 0.72 beta, while its volatility is 28.00% which is less volatile than S&P 500. In other hand, XBiotech Inc. has beta of 0.31 which is 69.00% less volatile than S&P 500.
6.3 and 5.9 are the respective Current Ratio and a Quick Ratio of Dynavax Technologies Corporation. Its rival XBiotech Inc.’s Current and Quick Ratios are 9.3 and 9.3 respectively. XBiotech Inc. has a better chance of clearing its pay short and long-term debts than Dynavax Technologies Corporation.
Dynavax Technologies Corporation and XBiotech Inc. Ratings and Recommendations are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Dynavax Technologies Corporation||0||0||3||3.00|
Dynavax Technologies Corporation’s upside potential is 257.14% at a $27 consensus price target.
Insider and Institutional Ownership
The shares of both Dynavax Technologies Corporation and XBiotech Inc. are owned by institutional investors at 85.9% and 13.2% respectively. Insiders owned roughly 1.3% of Dynavax Technologies Corporation’s shares. Comparatively, XBiotech Inc. has 37.5% of it’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Dynavax Technologies Corporation||-9.94%||-15.34%||-23.65%||-29.32%||-41.87%||1.97%|
For the past year Dynavax Technologies Corporation has weaker performance than XBiotech Inc.
XBiotech Inc. beats Dynavax Technologies Corporation on 7 of the 10 factors.
Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodyÂ’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The companyÂ’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.